Preclinical studies indicate that increased plasma levels of soluble NKG2D ligands in HNSCC patients, if depleted, restore the ability to kill the cell’s target in vitro [515,516]. This evidence concerns the gene KLRK1 and head and neck squamous cell carcinoma.